/content/mofsl-website-adobe/fragments/open-demat-popup
style
hide-in-desktop

US Stock Details

Get in-depth insights on US stocks, including fundamentals, financials, shareholding, peer comparison, and performance. Track key metrics, price trends, and market sentiment for informed decisions. Stay ahead with expert analysis and data-driven strategies at Motilal Oswal.

style
pb-0

FibroGen Inc

us-stock
To Invest in {{usstockname}}
/content/mofsl-website-adobe/demat-form-fields
style
sticky-block,pt-0
us-stock
style
pt-0
$8.2 0.005(0.5%) FGEN at 04 Dec 2025 03:46 PM Biotechnology
Lowest Today 8.11
Highest Today 8.155
Today’s Open 8.11
Prev. Close 8.08
52 Week High 21.94
52 Week Low 4.85
Day’s Range: Low 8.11 High 8.155
52-Week Range: Low 4.85 High 21.94
1 day return -
1 Week return -5.26
1 month return -26.63
3 month return -28.82
6 month return +2563.59
1 year return +1876.09
3 year return -49.98
5 year return -80.59
10 year return -

Institutional Holdings

Armistice Capital, LLC 8.31

Vanguard Group Inc 4.40

Vanguard Total Stock Mkt Idx Inv 2.82

PRIMECAP Management Company 2.22

BlackRock Inc 2.10

Marshall Wace Asset Management Ltd 1.79

Vanguard Capital Opportunity Inv 1.68

Geode Capital Management, LLC 1.09

HighTower Advisors, LLC 0.98

Vanguard Institutional Extnd Mkt Idx Tr 0.94

Fidelity Extended Market Index 0.55

Two Sigma Investments LLC 0.35

State Street Corp 0.34

Renaissance Technologies Corp 0.28

UBS Group AG 0.25

Group One Trading, LP 0.18

Extended Equity Market Fund K 0.18

Fidelity Total Market Index 0.17

Fidelity Series Total Market Index 0.15

Acadian Global Small-Cap Equity CIT Cl A 0.13

Spartan Extended Market Index Pool F 0.11

Northern Trust Extended Eq Market Idx 0.09

NT Ext Equity Mkt Idx Fd - L 0.09

NT Ext Equity Mkt Idx Fd - NL 0.08

Spartan Total Market Index Pool G 0.06

Vanguard Instl Ttl Stck Mkt Idx Tr 0.06

NT Ext Equity Mkt Idx Fd - DC - NL - T2 0.06

Vanguard Balanced Index Inv 0.06

Morgan Stanley - Brokerage Accounts 0.04

Goldman Sachs Group Inc 0.03

NT Ext Eq Mkt Indx Fd DC Lend T3 0.02

Tower Research Capital LLC 0.02

Blackstone Alternative Multi-Strategy I 0.02

Advisor Group Holdings, Inc. 0.02

Gfg Capital, LLC 0.01

Bank of America Corp 0.01

SSgA U.S. Total Market Index Strategy 0.01

Atlantic Trust Group, LLC 0.01

CIBC US Broad Market Index 0.00

SBI Securities Co Ltd 0.00

Market Status

Strong Buy: 0

Buy: 1

Hold: 1

Sell: 0

Strong Sell: 0

Fundamentals

Market Cap 32.69 M

PB Ratio 53.8258

PE Ratio 0.0

Enterprise Value 85.16 M

Total Assets 214.53 M

Volume 13747

Company Financials

Annual Revenue FY23:154981000 155.0M, FY22:140734000 140.7M, FY21:235309000 235.3M, FY20:176319000 176.3M, FY19:256577000 256.6M

Annual Profit FY23:136615000 136.6M, FY22:120454000 120.5M, FY21:222438000 222.4M, FY20:167450000 167.5M, FY19:255430000 255.4M

Annual Net worth FY23:-294175000 -294.2M, FY22:-295227000 -295.2M, FY21:-291030000 -291.0M, FY20:-189291000 -189.3M, FY19:-76970000 -77.0M

Quarterly Revenue Q3/2025:1076000 1.1M, Q2/2025:1348000 1.3M, Q1/2025:2739000 2.7M, Q3/2024:46333000 46.3M, Q2/2024:50641000 50.6M

Quarterly Profit Q3/2025:1134000 1.1M, Q2/2025:1263000 1.3M, Q1/2025:2487000 2.5M, Q3/2024:41038000 41.0M, Q2/2024:45463000 45.5M

Quarterly Net worth Q3/2025:200636000 200.6M, Q2/2025:-7603000 -7.6M, Q1/2025:4639000 4.6M, Q3/2024:-17084000 -17.1M, Q2/2024:-15544000 -15.5M

Fund house & investment objective

Company Information FibroGen, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapeutics to treat serious unmet medical needs. Its lead product candidates are Roxadustat, a small molecule inhibitor of hypoxia-inducible factor prolyl hydroxylase activity, which has completed Phase III clinical development for the treatment of anemia in chronic kidney disease in China, Europe, Japan, and other countries, as well as in Phase III clinical development for anemia related with myelodysplastic syndromes. Its pipeline products include FG-3165 and FG-3175, an anti-GAL-9 antibody for treatment of solid tumors. The company has collaboration agreements with Astellas Pharma Inc. and AstraZeneca AB. FibroGen, Inc. was incorporated in 1993 and is headquartered in San Francisco, California.

Organisation Biotechnology

Employees 225

Industry Biotechnology

CEO Mr. Thane Wettig

Trading and brokerage services provided by

Technology Services provided by Motilal Oswal Financial Services:

Disclaimer: These services are not for exchange traded products. The securities quoted are exemplary and not recommendatory. Please be informed that US Stocks are not exchange traded funds in India and Motilal Oswal Financial Services acts in the capacity of facilitator of this product. All disputes with respect to the transaction facilitation services, would not have access to Indian Exchange investor redressal forum or Arbitration mechanism in India. T&C apply*

Take your next step

Talk to our investment advisor for stock recommendations
Left
Get expert assistance for portfolio management
Right
style
align-center,button-arrow